Cannell & Co. Xencor Inc Call Options Transaction History
Cannell & Co.
- $3.01 Billion
- Q4 2023
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding XNCR
# of Institutions
204Shares Held
63.1MCall Options Held
3.9KPut Options Held
3K-
Black Rock Inc. New York, NY11.1MShares$223 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA9.12MShares$183 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA7MShares$141 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.33MShares$107 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.96MShares$79.7 Million0.01% of portfolio
About Xencor Inc
- Ticker XNCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,698,100
- Market Cap $1.2B
- Description
- Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...